Basic and Diluted Net Loss Per Share

6 Months Ended

Jun. 30, 2014

NOTE 6 – BASIC AND DILUTED NET LOSS PER SHARE

The Company computes net income (loss) per common share in accordance with FASB ASC 260, “Earnings Per Share”. Net income (loss) per share is based upon the weighted average number of outstanding common shares and the dilutive effect of common share equivalents, such as options and warrants to purchase common stock, convertible preferred stock and convertible notes, if applicable, that are outstanding each year. Basic and diluted earnings per share were the same at the reporting dates of the accompanying financial statements, as including common stock equivalents in the calculation of diluted earnings per share would have been anti-dilutive.

Common stock equivalents that were not included in diluted earnings per share at June 30, 2014 and 2013 are as follows:

	2014		2013
Stock options		39,910,000		52,920,000
Warrants		919,230		919,230
Convertible promissory notes		55,170,383		17,654,728
Common stock equivalents		95,999,613		71,493,958

- Definition

The entire disclosure for earnings per share.

+ References+ Details

CELLCYTE GENETICS CORP 10-Q